Over the past 30 years, the majority of (pre) clinical efforts to find an effective therapy for
Alzheimer's disease (AD) focused on clearing the β-amyloid peptide (Aβ) from the brain …

The inheritance of Apolipoprotein E4 (APOEε4) brings the highest genetic risk of Alzheimer's
disease (AD), arguably the highest genetic risk in human pathology. Since the discovery of …

Increasing evidence supports that age, APOE and sex interact to modulate Alzheimer's
disease (AD) risk, however the underlying pathways are unclear. One way that AD risk …

Although substantial progress has been made in the last two decades, there are still
important unfilled gaps in the understanding of the pathomechanism of Alzheimer's disease …

Many studies aim to detect the early phase of dementia. One of the major ways to achieve
this is to identify corresponding biomarkers, particularly immune blood biomarkers. The …

Alzheimer's disease (AD) is a complex neurological ailment that causes cognitive decline
and memory loss. Cholesterol metabolism dysregulation has emerged as a crucial element …

Background: Mild cognitive impairment (MCI) is considered a preclinical stage of
Alzheimer's disease (AD). People with MCI have a higher risk of developing dementia than …

Increasing evidence suggests that female individuals have a higher Alzheimer's disease
(AD) risk associated with post-menopausal loss of circulating estradiol (E2). However …

Depressive symptoms usually precede the cognitive decline in Alzheimer disease (AD) and
worsen the clinical outcome. However, the neural circuitry mediating early emotional …

Background/Objectives: Several studies have shown a relation between obesity and
cognitive decline, highlighting a significant global health challenge. In recent years, artificial …